American Society of Nephrology

Carla Nester, MD, discusses sustained proteinuria reduction and kidney function findings through 76 weeks of pegcetacoplan treatment.

Carla Nester, MD, discusses sustained proteinuria reduction and kidney function findings through 76 weeks of pegcetacoplan treatment.

Bradley Dixon, MD, discusses VALIANT+VALE data showing sustained proteinuria reduction and stable eGFR through 76 weeks in adolescents with C3G or IC-MPGN.

Bradley Dixon, MD, discusses VALIANT+VALE data showing sustained proteinuria reduction and stable eGFR through 76 weeks in adolescents with C3G or IC-MPGN.

In 101 Italian adults on stable RAS blockade, SGLT2 inhibitor add-on was tied to lower 12-month proteinuria but no eGFR slope change.

Kidney Week 2026 registry data linked a selective cytopheretic device to higher survival in children with septic AKI requiring CRRT.

IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.

Stephen Seliger, MD, and Michel Chonchol, MD, join Kidney Compass to discuss a pilot trial of empagliflozin in rapidly progressing ADPKD.

Emmanuel Montassier presented potassium data at 60 minutes from 398 adults treated for acute hyperkalemia in the ED.

Investigators will probe acid base metabolism and metabolomics to explain the blood pressure and potassium findings from DapaBalci-Leap.

David Leehey, MD, says about half of the 2376 enrolled veterans were taking an SGLT2 inhibitor at baseline.

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

An early behavioral activation therapy signal at 8 weeks didn’t hold, and bupropion brought more insomnia and confusion.

In interim V012 data, women on hemodialysis reached usable access months sooner with ATEV, said Prabir Roy-Chaudhury, MD, PhD.

Prabir Roy-Chaudhury, MD, PhD, explains how the ATEV is made and the research questions he wants answered next.

A retrospective cohort of 34,398 veterans found similar hospital days in VA and community dialysis settings across pandemic periods.

Balcinrenone lowered systolic BP by 14.1 mm Hg in stage 3 CKD, while combination therapy preserved dapagliflozin's glucosuric effect.

James Tumlin, MD, discusses RAINIER's proteinuria findings, dual APRIL/BAFF inhibition, safety, and the upcoming FDA decision.

In 1200 patients with solid tumors, creatinine-based eGFR identified CKD in 10.2% vs 18.9% by measured GFR, often missing chemotherapy dosing cutoffs.

Phase 2 BESTOW patient-reported outcomes show greater quality-of-life gains and fewer medication-related symptoms with tegoprubart vs tacrolimus at 1 year.

Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.

Longer GLP-1 RA exposure was also associated with a lower hospitalization burden in a cohort of 5,897 patients with type 2 diabetes.

A Kidney Week 2026 survey examines why patients miss dialysis, when barriers arise, and how outreach relates to rescheduling.

Jessica Kendrick, MD, MPH, discusses phase 3 PATH data showing upacicalcet reduced iPTH in hemodialysis patients with secondary hyperparathyroidism.

Christopher Chan, MD, discusses why digital counseling was linked to higher home KRT uptake only among motivationally ready patients with CKD.

Early RENEW-HD data support moving the 13 kg Neokidney to autonomous use testing, with dialysate calcium adjustments planned.

Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.

A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.

Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.